Inhaled drug combo aims to boost lung cancer treatment before surgery
NCT ID NCT06694454
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 4 times
Summary
This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage IB-IIIA NSCLC. Participants receive the inhaled drug for three days each cycle, plus IV chemo and immunotherapy, followed by tumor removal surgery. The goal is to find the safest and most effective dose and see if this combination can eliminate all cancer cells in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inhaled azacytidine (a drug that affects gene activity) combined with standard chemotherapy (carboplatin and paclitaxel) and durvalumab (an immunotherapy)
What this could lead to
If it works, this could lead to a new treatment option that helps shrink early-stage lung cancer before surgery, potentially reducing the chance of the cancer coming back.
What could go wrong
This is an early-phase trial with only 60 people, so the benefits are not proven yet. The inhaled drug is experimental for lung cancer, and side effects from the combination therapy could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••